1. Baseline patient characteristics by treatment group.
| Variables | n (%) | P | ||
| Group A (N=78) | Group B (N=148) | Group C (N=116) | ||
| Group A, chemotherapy-only group; Group B, trastuzumab combination group; Group C, lapatinib combination group; CNS, central nervous system; *, Totals exceed 100% because patients could have received more than one treatment. | ||||
| Age (year) [median (range)] | 44.5 (23−67) | 47.0 (24−75) | 43.5 (26−68) | 0.3451 |
| Hormone receptor status | 0.1979 | |||
| Positive | 41 (52.6) | 69 (46.6) | 46 (39.7) | |
| Negative | 37 (47.4) | 79 (53.4) | 70 (60.3) | |
| Number of metastatic sites | 0.4316 | |||
| 1 | 27 (34.6) | 56 (37.8) | 41 (35.3) | |
| 2 | 32 (40.0) | 59 (39.9) | 40 (34.5) | |
| 3 | 14 (17.9) | 20 (13.5) | 21 (18.1) | |
| ≥4 | 5 (6.4) | 13 (8.8) | 14 (12.1) | |
| Visceral metastases | 55 (70.5) | 105 (70.9) | 86 (74.1) | 0.8071 |
| CNS | 8 (10.3) | 10 (6.8) | 19 (16.4) | 0.0434 |
| Liver | 26 (33.3) | 51 (34.5) | 46 (39.7) | 0.5868 |
| Chemotherapy of the trial* | ||||
| Capecitabine | 25 (32.1) | 58 (39.2) | 97 (83.6) | <0.0001 |
| Vinorelbine | 20 (25.6) | 49 (33.1) | 9 (7.8) | <0.0001 |
| Taxane | 24 (30.8) | 33 (22.3) | 9 (7.8) | <0.0001 |
| Gemcitabine | 17 (21.8) | 13 (8.8) | 1 (0.9) | <0.0001 |
| Others | 12 (15.4) | 4 (2.7) | 1 (0.9) | <0.0001 |